Skip to content

Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section

Pruritus After Intrathecal Morphine in Cesarean Section: Incidence, Severity and Its Relation to Serum Serotonin Level

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03209427
Enrollment
40
Registered
2017-07-06
Start date
2014-04-02
Completion date
2016-09-21
Last updated
2017-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus

Keywords

morphine, pruritus, serotonin

Brief summary

Pruritus is the commonest side effect of intrathecal morphine especially in parturient, but the exact mechanism of pruritus is not clear. Many mechanisms have been suggested. Among these mechanisms is the activation of the 5-HT3 receptors by the intrathecally injected morphine.

Detailed description

Forty parturients underwent elective cesarean section under spinal anesthesia were divided into two groups of 20 each in this prospective randomized study. Group I received 100 µg of intrathecal morphine (ITM) mixed with 12 mg of 0.5% heavy bupivacaine (M100) while group II received 200 µg of ITM mixed with 12 mg of 0.5% heavy bupivacaine (M200). Two blood samples were taken from each patient for serotonin estimation, preoperatively and 4 hrs later. Postoperatively all patients were assessed for pruritus (incidence & severity), visual analog scale (VAS), first request of analgesia, and total analgesic dose required within 24 hrs.

Interventions

DRUGMorphine 100 μg

Intrathecal injection of morphine100 μg

DRUGMorphine 200 μg

Intrathecal injection of morphine 200 μg

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* ASA I - II term pregnant patients scheduled for elective cesarean section

Exclusion criteria

* patients with a known allergy to the study drugs * significant cardiac, respiratory, renal, neurological, or hepatic disease; -coagulation disorders * BMI \> 30 kg/m2 * any itchy skin diseases.

Design outcomes

Primary

MeasureTime frameDescription
Pruritus24 hours postoperativeincidence

Secondary

MeasureTime frameDescription
serotoninpreoperativeSerum level

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026